Amended Statement of Ownership: Solicitation (sc 14d9/a)
22 Juin 2018 - 12:44PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 14D-9
(RULE 14d-101)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES
EXCHANGE ACT OF 1934
(Amendment No. 5)
MATTERSIGHT CORPORATION
(Name of Subject Company)
MATTERSIGHT CORPORATION
(Name of Persons Filing Statement)
Common Stock, par value $0.01 per share
7% Series B Convertible Preferred Stock,
par value $0.01 per share
(Title of Class of Securities)
Common Stock: 577097108
(CUSIP Number of Class of Securities)
Kelly D. Conway
Chief Executive Officer
Mattersight Corporation
200 W. Madison Street, Suite 3100
Chicago, Illinois 60606
(877) 235-6925
(Name, address and telephone numbers
of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
|
Matthew P. Dubofsky
Steven J. Tonsfeldt
Cooley LLP
380 Interlocken Crescent
Suite 900
Broomfield, CO 80021-8023
(720) 566-4000
|
¨
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
This Amendment No. 5 to Schedule 14D-9 (this “Amendment
No. 5”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 previously filed by Mattersight
Corporation, a Delaware corporation (“Mattersight”), with the Securities and Exchange Commission on May 10, 2018, as
amended May 21, 2018, May 25, 2018, June 8, 2018 and June 12, 2018 (the “Schedule 14D-9”), relating to the tender offer
by NICE Systems, Inc. (“Parent”), NICE Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of
Parent (“Purchaser”), and NICE Ltd. (“NICE”), to purchase all of the issued and outstanding shares of Mattersight
Common Stock at a purchase price of $2.70 per share and all of the issued and outstanding shares of Mattersight 7% Series B Convertible
Preferred Stock at a purchase price of $7.80 per share, plus accrued but unpaid dividends payable thereon as of immediately prior
to the Effective Time, net to the holder thereof in cash, without interest and less applicable withholding taxes, upon the terms
and subject to the conditions set forth in the Offer to Purchase, dated May 10, 2018, and the related Letter of Transmittal, each
of which may be amended, supplemented or otherwise modified from time to time in accordance with the Merger Agreement.
Capitalized terms used but not defined in this Amendment No.
5 have the meanings ascribed to them in the Schedule 14D-9. The information in the Schedule 14D-9 is incorporated into this Amendment
No. 5 by reference to all applicable items in the Schedule 14D-9, except that such information is hereby amended and supplemented
to the extent specifically provided herein. Except as specifically noted herein, the information set forth in the Schedule 14D-9
remains unchanged. All page references are to pages in the Schedule 14D-9.
Item 2. Identity and Background of Filing Person.
Item 2 of the Schedule 14D-9 is hereby amended and supplemented
by adding the following paragraphs immediately after the seventh paragraph under the heading “Tender Offer” on page
2 of the Schedule 14D-9:
“On June 22, 2018, NICE, on behalf of Parent
and Purchaser, announced an extension of the expiration of the Offer to one minute after 11:59 p.m., New York time, on Friday,
July 6, 2018, unless the Offer is further extended or earlier terminated in accordance with the Merger Agreement. The Offer, which
was previously scheduled to expire at one minute after 11:59 p.m., New York time, on Thursday, June 21, 2018, was extended to allow
additional time for the satisfaction of the conditions to the Offer.
Continental Stock Transfer & Trust Company,
the depositary and paying agent for the Offer (the “Depositary”), has advised NICE, Parent, and Purchaser that, as
of 5:00 p.m., New York time, on Thursday, June 21, 2018, approximately (a) 29,630,455 shares of Common Stock had been validly tendered
in the Offer, and not validly withdrawn, and (b) 1,571,997 shares of Preferred Stock had been validly tendered in the Offer, and
not validly withdrawn, representing approximately 89.3% of the Shares outstanding on an as-converted to Common Stock basis. In
addition, 611,510 shares of Common Stock and 5,111 shares of Preferred Stock subject to notices of guaranteed delivery for which
such shares underlying the notices of guaranteed delivery have not been delivered to the Depositary have been delivered.
The full text of the press release issued by NICE
announcing the extension of the Offer is attached hereto as Exhibit (a)(5)(D) and is incorporated by reference herein.”
Item 9. Exhibits
Item 9 of the Schedule 14D-9 is hereby amended and supplemented
by adding the following exhibit:
Exhibit
|
Description
|
(a)(5)(D)
|
Press Release issued by NICE Ltd., on June 22, 2018 (incorporated by reference to Exhibit (a)(1)(J) to the Schedule TO)
|
SIGNATURES
After due inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this Amendment No. 5 to Schedule 14D-9 is true, complete and correct.
|
MATTERSIGHT CORPORATION
|
|
|
|
|
By:
|
/s/ David B. Mullen
|
|
|
Name: David B. Mullen
|
|
|
Title:
Chief Financial Officer
|
Dated: June 22, 2018
Matria Healthcare (NASDAQ:MATR)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Matria Healthcare (NASDAQ:MATR)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024